- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05876065
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
November 18, 2023 updated by: Wenjin Yin
Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
86
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wenjin Yin, M.D.
- Phone Number: 86(21)68385569
- Email: yinwenjin@renji.com
Study Locations
-
-
-
Shanghai, China, 200127
- Recruiting
- Renji Hospital, School of Medicine, Shanghai Jiaotong University
-
Contact:
- Wenjin Yin
- Phone Number: 86(21)68385569
- Email: yinwenjin@renji.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female, age≥18 years old
- ECOG≤2
- Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
- HR+/HER2+ or HR-/HER2+ or HR-/HER2-
- At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- Disease control (complete response + partial response + stable disease) after salvage treatment
- Expected survival ≥6 months
- Adequate organ function
Exclusion Criteria:
- during pregnancy and lactation
- Patients with central nervous system metastasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: capecitabine and cyclophosphamide (XC)
capecitabine and cyclophosphamide as maintenance therapy every 3 weeks
|
Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
|
Active Comparator: physician's choice
Any physician's choice as maintenance therapy (except for XC regimen).
|
Any physician's choice as maintenance therapy (except for XC regimen)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS)
Time Frame: From the date of starting maintenance therapy to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
|
PFS is defined as the time from the date of starting maintenance therapy to the date of disease progression or death from any cause, whichever occurs first.
|
From the date of starting maintenance therapy to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: From the date of starting maintenance therapy to the end of the treatment (up to approximately 1 year)]
|
Adverse events during maintenance therapy will be assessed according to the NCI CTCAE v5.0.
|
From the date of starting maintenance therapy to the end of the treatment (up to approximately 1 year)]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Wenjin Yin, M.D., Renji Hospital,School of Medicine, Shanghai Jiaotong University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
May 14, 2023
First Submitted That Met QC Criteria
May 16, 2023
First Posted (Actual)
May 25, 2023
Study Record Updates
Last Update Posted (Estimated)
November 21, 2023
Last Update Submitted That Met QC Criteria
November 18, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LY2023-073-A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
-
SanofiCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast CancerUnited States
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerJapan
Clinical Trials on XC
-
Kenneth BeerAllerganUnknownMandibular HypoplasiaUnited States
-
University of OklahomaACE Surgical Supply, Inc.CompletedOral Ridge PreservationUnited States
-
Össur EhfMethodist Rehabilitation Center; Baker Orthotics & Prosthetics; Virginia Prosthetics...CompletedAmputation | Prosthesis UserUnited States
-
University of BarcelonaCompletedQuality of Life | SatisfactionSpain
-
AllerganCompletedMid-facial Volume Deficit Related to AgingUnited States, Canada
-
AllerganCompletedSkin Smoothness of the CheeksUnited States, Puerto Rico
-
AllerganCompletedChin RetrusionUnited States
-
AllerganCompletedModerate to Severe Nasolabial FoldsUnited States
-
Baumann Cosmetic and Research InstituteCompleted
-
Dongkook Pharmaceutical Co., Ltd.CompletedNasolabial FoldsKorea, Republic of